Haloperidol

• UNSPSC Description:

  Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

• Target Antigen:

  Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Haloperidol.html

• Solubility:

  DMSO : 40 mg/mL (ultrasonic)

• Smiles:

  ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2

• Molecular Weight:

  375.86

• References & Citations:

  [1]Furuta Y, et al. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs. Br J Pharmacol. 1973 Jan;47(1):77-84|[2]Shah NS, et al. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice. J Pharmacol Exp Ther. 1973 Aug;186(2):297-304|[3]Lei K, et al. Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. Exp Anim. 2018 May 10;67(2):163-173. |[4]Guzen FP, et al. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. Curr Protoc Neurosci. 2019 Jun;88(1):e68.ACS Omega. 2020 Nov 15;5(46):29935-29942.|BMC Endocr Disord. 2021 Nov 23;21(1):235.|Br J Pharmacol. 2021 Apr 26.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell. 2023 Nov 22;186(24):5347-5362.e24.|Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380.|Environ Sci Technol. 2023 Sep 13.|Eur J Integr Med. 2021, 101322.|Eur J Pharmacol. 2023 Mar 8;175647.|Eur J Pharmacol. 2023 Nov 6:176174.|J Ethnopharmacol. 2021 Mar 9;113994.|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Behav Brain Res. 2022 Jan 17;113759.|EMBO Rep. 2022 Jan 17;e53191.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  52-86-8